- Conditions
- Leukemia, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Interventions
- busulfan, cyclophosphamide, methylprednisolone, allogeneic bone marrow transplantation, in vitro-treated bone marrow transplantation
- Drug · Procedure
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 19 Years to 55 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2001
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Columbia, South Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 721–744
of 13,266
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Vaccine Reaction
- Interventions
- FMP013, ALFQ
- Drug
- Lead sponsor
- U.S. Army Medical Research and Development Command
- Federal
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Silver Spring, Maryland
- Conditions
- Influenza Immunization, Healthy Volunteers
- Interventions
- Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2021-2022 formulation, Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2021-2022 formulation
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 6 Months and older
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 2
- States / cities
- Bardstown, Kentucky • Salt Lake City, Utah
- Conditions
- Pain, Migraine Disorders
- Interventions
- PF-04427429, Normal saline
- Biological · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 31 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 3
- States / cities
- Miami, Florida • Dallas, Texas
- Conditions
- Atopic Dermatitis
- Interventions
- Nevisense electrical impedance spectroscopy
- Device
- Lead sponsor
- Castle Biosciences Incorporated
- Industry
- Eligibility
- 12 Years to 89 Years
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 16
- States / cities
- Phoenix, Arizona • Los Angeles, California • Tampa, Florida + 13 more
- Conditions
- Graves' Disease
- Interventions
- IMVT-1402, Placebo
- Drug
- Lead sponsor
- Immunovant Sciences GmbH
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 33
- States / cities
- Tucson, Arizona • Concord, California • Aurora, Colorado + 28 more
- Conditions
- Alzheimer Disease, Memory Loss
- Interventions
- Transcranial alternating current stimulation (tACS)
- Device
- Lead sponsor
- Hebrew SeniorLife
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Sebaceous Hyperplasia, Skin Abnormalities, Skin Lesion
- Interventions
- Nano-Pulse Stimulation (NPS)
- Device
- Lead sponsor
- Pulse Biosciences, Inc.
- Industry
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • Sacramento, California • Santa Monica, California + 3 more
- Conditions
- Cognitive/Functional Effects, Colorectal Cancer, Long-term Effects Secondary to Cancer Therapy in Adults
- Interventions
- cognitive assessment, magnetic resonance imaging, management of therapy complications
- Procedure
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- Not listed
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Respiratory Syncytial Virus Infection
- Interventions
- Sisunatovir, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 14
- States / cities
- Garden Grove, California • Westminster, California • Miami, Florida + 9 more
- Conditions
- Cutaneous Lupus, Systemic Lupus Erythematosus
- Interventions
- Tofacitinib
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 2
- States / cities
- Cincinnati, Ohio • Cleveland, Ohio
- Conditions
- Primary Sclerosing Cholangitis
- Interventions
- Cilofexor, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 419 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 82
- States / cities
- Glendale, Arizona • Phoenix, Arizona • Coronado, California + 65 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Iyengar Yoga
- Behavioral
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 16 Years to 35 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Influenza, Human
- Interventions
- D-SUIV cH8/1N1+AS03, D-SUIV cH5/1N1+AS03, D-SUIV cH11/1N1+AS03, D-SUIV cH8/1N1+AS01, D-SUIV cH5/1N1+AS01, D-SUIV cH11/1N1+AS01, D-SUIV cH8/1N1, D-SUIV cH5/1N1, D-SUIV cH11/1N1, Placebo, Fluarix Quadrivalent
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 39 Years
- Enrollment
- 470 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 5
- States / cities
- South Miami, Florida • Wichita, Kansas • Rochester, New York + 2 more
- Conditions
- Prostatic Cancer, Castration-Resistant
- Interventions
- JSB462, AAA617
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 10
- States / cities
- Duarte, California • Santa Monica, California • Denver, Colorado + 7 more
- Conditions
- HIV Infections
- Interventions
- rgp120/HIV-1IIIB, rgp120/HIV-1MN
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Ends 1995
- U.S. locations
- 3
- States / cities
- St Louis, Missouri • Philadelphia, Pennsylvania • Seattle, Washington
- Conditions
- ADHD
- Interventions
- Lisdexamfetamine
- Drug
- Lead sponsor
- Jeffrey Newcorn
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, Adult Acute Promyelocytic Leukemia With PML-RARA, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia, Childhood Acute Myeloid Leukemia in Remission, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
- Interventions
- Laboratory Biomarker Analysis
- Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Not listed
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive
- Interventions
- Bosutinib, Imatinib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 536 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 65
- States / cities
- Anaheim, California • Atlanta, Georgia • Honolulu, Hawaii + 40 more
- Conditions
- Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4, Advanced Breast Cancer, Advanced Lung Carcinoma, NSCLC, NSCLC, Recurrent, NSCLC Stage IV, Relapsed Cancer, Relapse/Recurrence, Recurrent Breast Cancer, Recurrent NSCLC, Platinum-resistant Ovarian Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Endometrioid Tumor, High Grade Serous Carcinoma, Ovarian Epithelial Cancer
- Interventions
- LYL797
- Biological
- Lead sponsor
- Lyell Immunopharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 18
- States / cities
- Scottsdale, Arizona • Santa Monica, California • New Haven, Connecticut + 15 more
- Conditions
- Influenza
- Interventions
- Seasonal Influenza DNA vaccine, TIV
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 316 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 4
- States / cities
- Stanford, California • Iowa City, Iowa • St Louis, Missouri + 1 more
- Conditions
- Melanoma, Non-small Cell Lung Carcinoma (NSCLC), Renal Cell Carcinoma (RCC), Small-cell Lung Cancer, Head and Neck Squamous Cell Cancer, Classical Hodgkin Lymphoma, Primary Mediastinal Large B-Cell Lymphoma, Urothelial Carcinoma, Microsatellite Instability-High Cancer, Gastric Cancer, Esophageal Cancer, Cervical Cancer, Hepatocellular Carcinoma, Merkel Cell Carcinoma, Brain Metastases, Adult
- Interventions
- LITT + Pembrolizumab
- Combination Product
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 2
- States / cities
- Gainesville, Florida • Jacksonville, Florida
- Conditions
- Cardiac Toxicity, Chemotherapeutic Agent Toxicity, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- exercise intervention
- Behavioral
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Chronic Kidney Disease
- Interventions
- Volenrelaxin, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 16
- States / cities
- Downey, California • Evergreen Park, Illinois • Hinsdale, Illinois + 13 more